In this case, we selected SOAT1, an enzyme catalyzing the formation of fatty acid-cholesterol esters, which was indicated as a possible drug target in adrenocortical carcinoma (Sbiera et al., 2015) and glioblastoma (Geng et al., 2016) for our validation. Here, SOAT1 is linked to glioblastoma.